GTC Biotherapeutics Inc

GTC Biotherapeutics — Investor Presentation (January 2010)

21 slides from GTC Biotherapeutics's investor presentation, Jan 8, 2010

  1. Slide 1: Corporate Presentation January 2010

    Corporate Presentation January 2010 Exhibit 99.2 NASDAQ: GTCB www.gtc-bio.com

  2. Slide 2: Safe Harbor Statement

    2 Safe Harbor Statement This presentation contains forward-looking statements that reflect GTC Biotherapeutics management’s current view of future events and operations. These forward- looking statements are based on assumptions, external factors, uncertainties and other risks that are detailed in t

  3. Slide 3: GTC Biotherapeutics

    3 GTC Biotherapeutics Validated “Game-Changing” Production Technology Recombinant plasma proteins Biosimilar/biobetter antibodies Enabling, scalable, cost-effective Validated regulatory path and infrastructure ATryn ® Recombinant Human Antithrombin Approved in US & EU Secured US commercialization pa

  4. Slide 4: Strategic Goals for Value Creation

    4 Strategic Goals for Value Creation Develop Biosimilar and Biobetter Antibodies Focus on oncology & autoimmune indications CD20, HER2, EGFR and TNF MAbs Enhanced ADCC biobetters Outside key cell culture MAb IP Pipeline Advance 2 products into the clinic in 2010 Factor VIIa (hemophilia) into Phase I

  5. Slide 5: Technology to Products

    5 Technology to Products Lower Production Costs Enabling difficult to express proteins enhanced ADCC/glycosylation High Volume Production unconstrained supply scaleable/flexible established infrastructure Validated Regulatory Path (US/EU) Protected by Intellectual Property proprietary IP (2021) and

  6. Slide 6: GTC Product Pipeline

    6 GTC Product Pipeline Recombinant Plasma Proteins ATryn ® (US/EU) hereditary deficiency acquired deficiencies Factor VIIa (LFB) hemophilia Factor IX (LFB) hemophilia AFP MS and MG Biosimilar/Biobetter Monoclonal Antibodies TG20 (LFB) oncology & autoimmune HER2, TNF, EGFR oncology & autoimmune Produ

  7. Slide 7: Partnerships

    7 Partnerships Key Component of GTC’s strategy Share product rewards and risks with partners Financial support for clinical development and commercialization Established Partners Commercialization partnership ATryn ® US partnership with Lundbeck $257M development and commercialization deal Developme

  8. Slide 8: Recombinant Plasma Protein Products

    8 Recombinant Plasma Protein Products Focused portfolio FVIIa, FIX AFP antithrombin (ATryn ® ) Addressing large, established markets Deliver: unconstrained supply Ensure: safe products Provide: lower COGS

  9. Slide 9: ATryn Recombinant Human Antithrombin

    9 ATryn ® Recombinant Human Antithrombin Anticoagulant and Anti-Inflammatory Broad range of therapeutic indications FDA & EMEA Approved Hereditary Deficiency Product Unique Selling Points Safe Consistent, reliable supply Robust clinical data package Only recombinant product Commercial sales in US an

  10. Slide 10: Antithrombin Deficiencies

    10 Antithrombin Deficiencies Genetic disease/orphan indication US Incidence 1:3000 High risk of venous thrombosis and pulmonary embolism during trauma, surgery and childbirth Disease-associated antithrombin deficiency Heparin resistance/CABG DIC Preeclampsia Burns/Trauma Hereditary Deficiency Acquir

  11. Slide 11: ATryn Commercial Strategy

    11 ATryn ® Commercial Strategy EMEA Approved in 2006 HD surgical cases Label expansion - childbirth Secure EU Commercial Partner Expand EU commercial availability Maximize EU sales in HD Geographical Expansion Secure commercial partners Canada Japan Middle East Maximize sales Commercial Partner: Lun

  12. Slide 12: Hemophilia

    12 Hemophilia Orphan Diseases (US >20,000 patients) Hemophilia A: FVIII deficient Hemophilia B: FIX deficient Hemophiliacs with inhibitors to FVIII or FIX FVIIa treats both conditions Overall Markets >$6B FVIIa: NovoSeven ® >$1.2B (2008) FIX: BeneFIX ® >$600M (2008) Genetic Diseases VIIa IX Large, G

  13. Slide 13: Factors VIIa and IX

    13 Factors VIIa and IX Expand markets with strong commercial partners Acute and prophylactic treatments Additional geographies Expand Labeling e.g. trauma, surgery Strategy Difficult to produce in cell culture Comparable to NovoSeven ® Discounted pricing Status: Established production line Data show

  14. Slide 14: Biotherapeutics

    cz Biotherapeutics

  15. Slide 15: Significant Market Opportunity for AFP

    15 Based on: Pre-clinical evidence shows efficacy in robust MS animal models Human safety data with favorable side-effect profile (>200 patients) Competitive COGS Convenient administration by subcutaneous injection Potential: 1st line therapy for MS 2nd line therapy for MG Other autoimmune CNS disea

  16. Slide 16: MAbs - A Manufacturing Challenge

    MAbs - A Manufacturing Challenge 16 ~24 kg ~15 kg IFN- IFN- hGH G-CSF EPO ERT >2500 kg

  17. Slide 17: Monoclonal Antibodies

    Monoclonal Antibodies Proven, competitive for MAb production >20 MAbs produced Easy scalability (10 – 1000+ kg) COGS, CapEx Avoids key cell culture MAb patents TG20 (CD20 MAb) (LFB JV) Oncology/autoimmune disease Target specificity similar to Rituxan Enhanced ADCC + similar CDC HER-2, TNF and EGFR i

  18. Slide 18: Goal: Cash Flow Positive by 2012

    18 Goal: Cash Flow Positive by 2012 2010 2011 Development • ATryn ® initiate PIII HR • FVIIa conduct Phase I • AFP initiate Phase II • Biosimilar characterization Partnering • ATryn ® EU • AFP • Biosimilar(s ) Development • FVIIa initiate Phase II/III • AFP conclude Phase II • FIX file IND • TG20 Ph

  19. Slide 19: GTC Fundamentals

    19 GTC Fundamentals Validated “game-changing” production platform enables production of difficult to express proteins easily scalable for high volume products cost competitive (COGS and CapEx) Demonstrated naturally enhanced ADCC MAbs generate high value 2nd generation oncology MAbs Recombinant vers

  20. Slide 20: Biotherapeutics

    Bioth peutics

  21. Slide 21: Forward-Looking Statements

    Forward-Looking Statements This slide presentation contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, including without limitation statements related to GTC’s plans to enter into partnerships, build upon existing strategic relationships, maximize

GTC Biotherapeutics — Investor Presentation (January 2010) on 6ix